[1] Rocco A, Compare D, Angrisani D, et al. Alcoholic disease: liver and beyond. World J Gastroenterol, 2014, 20(40): 14652-14659. [2] Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol, 2017, 3(36): 6549-6570. [3] 王飞, 康定理, 胡秀琼, 等. 硫普罗宁联合拉米夫定在肺结核合并慢性乙型肝炎治疗中的作用. 中国药房, 2016, 27(29): 4112-4115. [4] Di Miceli M, Gronier B. Pharmacology, systematic review and recent clinical trials of metadoxine. Rev Recent Clin Trials, 2018 13(2): 114-125. [5] 李良平. 酒精性肝病诊断现状. 实用肝脏病杂志, 2014, 17(1): 9-11. [6] Gkolfakis P, Dimitriadis G, Triantafyllou K. Gut microbiota and non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int, 2015, 14(6): 572-581. [7] Mathurin P, Bataller R. Trends in the management and burden of alcoholic liver disease. J Hepatol, 2015, 62(1): 38-46. [8] 张莉, 阎明, 江堤, 等. 乙醇抑制蛋白酶体诱导酒精性肝病模型大鼠肝脏线粒体凋亡. 中华实用诊断与治疗杂志, 2016, 30(1): 35-38. [9] Williams MJ, Clouston AD, Forbes SJ. Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. Gastroenterology, 2014, 146(2): 349-356. [10] Tanwar S, Trembling PM, Hogan BJ, et al. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy. Eur J Gastroenterol Hepatol, 2017, 29(3): 289-296. [11] 杨立新. 去脂软肝汤联合硫普罗宁治疗酒精性肝病的疗效分析. 检验医学与临床, 2015, 12(4): 492-494. [12] Tang MC, Cheng L, Qiu L, et al. Efficacy of tiopronin in treatment of severe non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci, 2014, 18(2): 160-164. [13] Shenoy KT, Balakumaran LK, Mathew P, et al. Metadoxine versus placebo for the treatment of non-alcoholic steatohepatitis: A randomized controlled trial. J Clin Exp Hepatol, 2014, 4(2): 94-100. [14] Peeters G, Debbaut C, Cornillie P, et al. A multilevel modeling framework to study hepatic perfusion characteristics in case of liver cirrhosis. J Biomech Eng, 2015, 137(5): 51007. [15] Kawanaka H, Akahoshi T, Kinjo N, et al. Effect of laparoscopic splenectomy on portal haemodynamics in patients with liver cirrhosis and portal hypertension. Br J Surg, 2014, 101(12): 1585-1593. [16] 宋秀丽. 硫普罗宁联合丹参注射液治疗酒精性肝病临床疗效. 肝脏, 2015, 20(9): 711-715. [17] Kedrowski BL1, Gutow JH, Stock G, et al. Glutathione reductase activity with an oxidized methylated glutathione analog. J Enzyme Inhib Med Chem, 2014, 29(4): 491-494. [18] Younossi Z, Henry L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology, 2016, 150(8): 1778-1785. [19] Oğguz D, Ünal HÜ, Eroğlu H, et al. Aortic flow propagation velocity, epicardial fat thickness, and osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease. Anatol J Cardiol, 2016, 16(12): 974-979. [20] 陈婷, 叶晓光. 常用非酒精性脂肪性肝病药物治疗方案的药物经济学评价. 肝脏, 2017, 22(9): 794-799. [21] Uchida H, Nakajima Y, Ohtake K, et al. Protective effects of oral glutathione on fasting-induced intestinal atrophy through oxidative stress. World J Gastroenterol, 2017, 23(36): 6650-6664. |